Desmond Padhi

Vice President of Medical Sciences at Amgen, Inc.

Desmond Padhi

Desmond Padhi

Vice President of Medical Sciences at Amgen, Inc.

Biography

Dr. Desmond Padhi is on the Board of Directors at Kyverna Therapeutics, Inc. Dr. Padhi was previously employed as a Chief Executive Officer by Capsida Biotherapeutics, Inc.

Overview
RelSci Relationships

1757

Number of Boards

2

Contact Data
Trying to get in touch with Desmond Padhi? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Desmond Padhi likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Kyverna Therapeutics

Relationship likelihood: Strong

Managing Director at Westlake Village BioPartners

Relationship likelihood: Strong

Interim Chief Medical Officer & Head of Development at Nektar Therapeutics

Relationship likelihood: Strong

Co-Founder at Vida Ventures LLC

Relationship likelihood: Average

Venture Partner at Versant Venture Management LLC

Relationship likelihood: Average

Professor, Department of Pathology at Stanford University

Relationship likelihood: Average

Member, Scientific Advisory Board at Kyverna Therapeutics

Relationship likelihood: Average

Member, Scientific Advisory Board at Kyverna Therapeutics

Relationship likelihood: Average

Managing Partner at Ablon, Lewis, Bass & Gale LLP

Relationship likelihood: Average

Vice President Community & Employer Relations at Los Robles Hospital & Medical Center

Relationship likelihood: Average

Paths to Desmond Padhi
Potential Connections via
Relationship Science
You
Desmond Padhi
Vice President of Medical Sciences at Amgen, Inc.
Career History
Vice President of Medical Sciences
Tenure Unconfirmed

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Other Affiliations

Desmond Padhi is affiliated with Amgen, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Desmond Padhi. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Desmond Padhi's profile does not indicate a business or promotional relationship of any kind between RelSci and Desmond Padhi.